<?xml version='1.0' encoding='utf-8'?>
<document id="31039308"><sentence text="Dissecting the Contribution of OATP1B1 to Hepatic Uptake of Statins Using the OATP1B1 Selective Inhibitor Estropipate." /><sentence text="Identification of a selective inhibitor of organic anion transporting polypeptide (OATP) 1B1 is critical in order to determine the contribution of OATP1B1-mediated uptake of investigational drugs into human hepatocytes for successful in vitro-to-in vivo extrapolation (IVIVE) of hepatic uptake and drug-drug interaction (DDI)" /><sentence text=" The following study examined the inhibitory effects of estropipate (EPP) on major sinusoidal drug uptake transporters and explored its utility regarding IVIVE of statin hepatic disposition"><entity charOffset="56-67" id="DDI-PubMed.31039308.s3.e0" text="estropipate" /><entity charOffset="69-72" id="DDI-PubMed.31039308.s3.e1" text="EPP" /><pair ddi="false" e1="DDI-PubMed.31039308.s3.e0" e2="DDI-PubMed.31039308.s3.e0" /><pair ddi="false" e1="DDI-PubMed.31039308.s3.e0" e2="DDI-PubMed.31039308.s3.e1" /></sentence><sentence text=" EPP and its free-base form (i"><entity charOffset="1-3" id="DDI-PubMed.31039308.s4.e0" text="EPP" /></sentence><sentence text="e" /><sentence text=", estrone sulfate) showed a potent and high degree of selectivity in inhibiting the OATP1B1-mediated transport of rosuvastatin with an IC50 value averaging 0"><entity charOffset="2-17" id="DDI-PubMed.31039308.s6.e0" text="estrone sulfate" /><entity charOffset="114-126" id="DDI-PubMed.31039308.s6.e1" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.31039308.s6.e0" e2="DDI-PubMed.31039308.s6.e0" /><pair ddi="false" e1="DDI-PubMed.31039308.s6.e0" e2="DDI-PubMed.31039308.s6.e1" /></sentence><sentence text="05 ± 0" /><sentence text="01 and 0" /><sentence text="12 ± 0" /><sentence text="07 μM for human and cynomolgus monkey OATP1B1 (hOATP1B1 and cOATP1B1), respectively, whereas weak inhibition was observed for human and monkey OATP1B3, OATP2B1, sodium-taurocholate cotransporting polypeptide (NTCP), organic anion transporter 2, and organic cation transporter 1 with IC50 values ranging from 8"><entity charOffset="161-180" id="DDI-PubMed.31039308.s10.e0" text="sodium-taurocholate" /></sentence><sentence text="6 to 64" /><sentence text="0 μM" /><sentence text=" EPP, together with rifamycin SV, was subsequently used to determine the fractions of hepatic uptake clearance ( fT) of statins, including rosuvastatin, pitavastatin, and dehydropravastatin, which are reported to be mediated by OATP1B1, OATP1B3, OATP2B1, and NTCP"><entity charOffset="20-32" id="DDI-PubMed.31039308.s13.e0" text="rifamycin SV" /><entity charOffset="139-151" id="DDI-PubMed.31039308.s13.e1" text="rosuvastatin" /><entity charOffset="153-165" id="DDI-PubMed.31039308.s13.e2" text="pitavastatin" /><entity charOffset="171-189" id="DDI-PubMed.31039308.s13.e3" text="dehydropravastatin" /><entity charOffset="237-244" id="DDI-PubMed.31039308.s13.e4" text="OATP1B3" /><entity charOffset="246-253" id="DDI-PubMed.31039308.s13.e5" text="OATP2B1" /><entity charOffset="1-7" id="DDI-PubMed.31039308.s13.e6" text="EPP" /><pair ddi="false" e1="DDI-PubMed.31039308.s13.e6" e2="DDI-PubMed.31039308.s13.e6" /><pair ddi="false" e1="DDI-PubMed.31039308.s13.e6" e2="DDI-PubMed.31039308.s13.e0" /><pair ddi="false" e1="DDI-PubMed.31039308.s13.e6" e2="DDI-PubMed.31039308.s13.e1" /><pair ddi="false" e1="DDI-PubMed.31039308.s13.e6" e2="DDI-PubMed.31039308.s13.e2" /><pair ddi="false" e1="DDI-PubMed.31039308.s13.e6" e2="DDI-PubMed.31039308.s13.e3" /><pair ddi="false" e1="DDI-PubMed.31039308.s13.e6" e2="DDI-PubMed.31039308.s13.e4" /><pair ddi="false" e1="DDI-PubMed.31039308.s13.e6" e2="DDI-PubMed.31039308.s13.e5" /><pair ddi="false" e1="DDI-PubMed.31039308.s13.e0" e2="DDI-PubMed.31039308.s13.e0" /><pair ddi="false" e1="DDI-PubMed.31039308.s13.e0" e2="DDI-PubMed.31039308.s13.e1" /><pair ddi="false" e1="DDI-PubMed.31039308.s13.e0" e2="DDI-PubMed.31039308.s13.e2" /><pair ddi="false" e1="DDI-PubMed.31039308.s13.e0" e2="DDI-PubMed.31039308.s13.e3" /><pair ddi="false" e1="DDI-PubMed.31039308.s13.e0" e2="DDI-PubMed.31039308.s13.e4" /><pair ddi="false" e1="DDI-PubMed.31039308.s13.e0" e2="DDI-PubMed.31039308.s13.e5" /><pair ddi="false" e1="DDI-PubMed.31039308.s13.e1" e2="DDI-PubMed.31039308.s13.e1" /><pair ddi="false" e1="DDI-PubMed.31039308.s13.e1" e2="DDI-PubMed.31039308.s13.e2" /><pair ddi="false" e1="DDI-PubMed.31039308.s13.e1" e2="DDI-PubMed.31039308.s13.e3" /><pair ddi="false" e1="DDI-PubMed.31039308.s13.e1" e2="DDI-PubMed.31039308.s13.e4" /><pair ddi="false" e1="DDI-PubMed.31039308.s13.e1" e2="DDI-PubMed.31039308.s13.e5" /><pair ddi="false" e1="DDI-PubMed.31039308.s13.e2" e2="DDI-PubMed.31039308.s13.e2" /><pair ddi="false" e1="DDI-PubMed.31039308.s13.e2" e2="DDI-PubMed.31039308.s13.e3" /><pair ddi="false" e1="DDI-PubMed.31039308.s13.e2" e2="DDI-PubMed.31039308.s13.e4" /><pair ddi="false" e1="DDI-PubMed.31039308.s13.e2" e2="DDI-PubMed.31039308.s13.e5" /><pair ddi="false" e1="DDI-PubMed.31039308.s13.e3" e2="DDI-PubMed.31039308.s13.e3" /><pair ddi="false" e1="DDI-PubMed.31039308.s13.e3" e2="DDI-PubMed.31039308.s13.e4" /><pair ddi="false" e1="DDI-PubMed.31039308.s13.e3" e2="DDI-PubMed.31039308.s13.e5" /><pair ddi="false" e1="DDI-PubMed.31039308.s13.e4" e2="DDI-PubMed.31039308.s13.e4" /><pair ddi="false" e1="DDI-PubMed.31039308.s13.e4" e2="DDI-PubMed.31039308.s13.e5" /></sentence><sentence text=" Finally, the magnitudes of in vivo inhibition of rosuvastatin clearance caused by EPP and rifampin in cynomolgus monkeys were predicted by using individual transporter IC50 and fT (AUC fold change 1"><entity charOffset="50-62" id="DDI-PubMed.31039308.s14.e0" text="rosuvastatin" /><entity charOffset="91-99" id="DDI-PubMed.31039308.s14.e1" text="rifampin" /><entity charOffset="83-90" id="DDI-PubMed.31039308.s14.e2" text="EPP" /><pair ddi="false" e1="DDI-PubMed.31039308.s14.e0" e2="DDI-PubMed.31039308.s14.e0" /><pair ddi="false" e1="DDI-PubMed.31039308.s14.e0" e2="DDI-PubMed.31039308.s14.e2" /><pair ddi="false" e1="DDI-PubMed.31039308.s14.e0" e2="DDI-PubMed.31039308.s14.e1" /><pair ddi="false" e1="DDI-PubMed.31039308.s14.e2" e2="DDI-PubMed.31039308.s14.e2" /><pair ddi="false" e1="DDI-PubMed.31039308.s14.e2" e2="DDI-PubMed.31039308.s14.e1" /></sentence><sentence text="28 vs 1" /><sentence text="21, 2" /><sentence text="71 vs 1" /><sentence text="75, and 3" /><sentence text="35 vs 2" /><sentence text="83, respectively)" /><sentence text=" These results suggest that EPP is an appropriate OATP1B1-selective inhibitor to establish the relative contribution of OATP1B1 to hepatic uptake in vitro and to discern the role of OATP1B1 in hepatic disposition in vivo"><entity charOffset="28-30" id="DDI-PubMed.31039308.s21.e0" text="EPP" /></sentence><sentence text="" /></document>